Pfizer is currently rated as a Buy by analysts who believe the company's stock remains undervalued by the market [1].
This valuation suggests a potential recovery for the pharmaceutical giant as it pivots its commercial strategy and diversifies its product offerings to drive growth. The shift comes as the company attempts to balance soft primary care performance with expanding specialty care [2].
Market analysts estimate a 16% nominal upside for Pfizer stock [1]. Additionally, the stock currently offers a dividend yield of approximately seven percent [1]. These figures are supported by a diversified and expanding product portfolio that analysts said is not yet fully reflected in the share price [1].
To streamline operations, Pfizer updated its commercial structure in Q1 2026 [2]. The company moved its biosimilars, generic sterile injectables, and off-patent branded products into a newly created Hospital and Biosimilars portfolio [2]. This new entity operates within the broader Biopharma segment [2].
The reorganization is intended to create a more efficient framework for managing products that no longer hold patent protection. By consolidating these assets, Pfizer aims to maintain its footprint in the hospital sector while continuing to scale its specialty care initiatives [2].
“Pfizer stock is rated a Buy with an estimated 16% nominal upside”
Pfizer is attempting to decouple its growth trajectory from the volatility of primary care by leaning into specialty care and biosimilars. The creation of the Hospital and Biosimilars portfolio indicates a strategic move to maximize the lifecycle of off-patent assets, ensuring a steady revenue stream while the company pursues new high-margin innovations.
